NASDAQ:ALEC Alector - ALEC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.09 -0.22 (-3.49%) (As of 03/30/2023 03:45 PM ET) Add Compare Share Share Today's Range$6.05▼$6.4250-Day Range$5.85▼$9.8452-Week Range$5.76▼$15.39Volume215,310 shsAverage Volume565,706 shsMarket Capitalization$505.65 millionP/E RatioN/ADividend YieldN/APrice Target$15.38 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Alector MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside152.0% Upside$15.38 Price TargetShort InterestBearish9.06% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.68Based on 2 Articles This WeekInsider TradingSelling Shares$180,802 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.14) to ($2.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector120th out of 999 stocksBiological Products, Except Diagnostic Industry19th out of 166 stocks 4.2 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.38, Alector has a forecasted upside of 152.0% from its current price of $6.10.Amount of Analyst CoverageAlector has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.06% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Alector has recently increased by 1.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alector is -0.92. Previous Next 3.2 News and Social Media Coverage News SentimentAlector has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alector this week, compared to 1 article on an average week.Search Interest6 people have searched for ALEC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Alector to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $180,802.00 in company stock.Percentage Held by Insiders12.89% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.96% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($3.14) to ($2.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alector (NASDAQ:ALEC) StockAlector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.Read More Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address ALEC Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comAlector (NASDAQ:ALEC) Shares Down 4.7% After Insider SellingMarch 23, 2023 | americanbankingnews.comArnon Rosenthal Sells 15,186 Shares of Alector, Inc. (NASDAQ:ALEC) StockMarch 30, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 28, 2023 | finance.yahoo.comAlector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateFebruary 17, 2023 | finance.yahoo.comAlector, Inc. (NASDAQ:ALEC) is a favorite amongst institutional investors who own 64%February 16, 2023 | finance.yahoo.comAlector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?January 28, 2023 | finance.yahoo.comAlector, Inc. (ALEC) Stock Historical Prices & Data - Yahoo FinanceDecember 21, 2022 | finance.yahoo.comWe're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn RateMarch 30, 2023 | WealthPop (Ad)Adam Mesh: “This Strategy Saved My Trading Career”Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. December 11, 2022 | marketwatch.comOnline Medical Market New Innovations and Future Expansion 2023-2028 with Top Countries DataNovember 10, 2022 | finance.yahoo.comAlector Third Quarter 2022 Earnings: Misses ExpectationsNovember 4, 2022 | finance.yahoo.comAlector (NASDAQ:ALEC) investors are sitting on a loss of 65% if they invested a year agoOctober 13, 2022 | globenewswire.comAlector Announces Promotion of Clare Hunt to Chief People Officer - GlobeNewswireOctober 13, 2022 | finance.yahoo.comAlector Announces Promotion of Clare Hunt to Chief People OfficerOctober 10, 2022 | reuters.comALEC.O - Alector Inc | Stock Price & Latest News | ReutersOctober 7, 2022 | finance.yahoo.comAlector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo FinanceOctober 6, 2022 | globenewswire.comAlector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswireOctober 4, 2022 | seekingalpha.comAlector Stock: Advancement Of Third AD Drug Brings About Huge Potential (NASDAQ:ALEC) - Seeking AlphaOctober 3, 2022 | benzinga.comTesla, Credit Suisse And Some Other Big Stocks Moving Lower In Today’s Pre-Market Session - ABB (NYSE:ABB - BenzingaOctober 3, 2022 | uk.investing.comTesla, Credit Suisse And Some Other Big Stocks Moving Lower In Today's Pre-Market Session By Benzinga - Investing.com UKSeptember 20, 2022 | nasdaq.comAdd Up The Parts: ESGV Could Be Worth $86 - NasdaqSeptember 13, 2022 | finance.yahoo.comAlector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD) - Yahoo FinanceSeptember 12, 2022 | benzinga.comAlector (NASDAQ:ALEC) – Moore Kuehn, PLLC Encourages Investors of Alector, Inc. to Contact Law Firm - BenzingaSeptember 12, 2022 | benzinga.comAlector (NASDAQ:ALEC) – Alector Initiates Phase 1 Clinical Trial Of AL044 For The Treatment Of Alzheimer' - BenzingaSeptember 12, 2022 | globenewswire.comAlector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD) - GlobeNewswireSeptember 12, 2022 | finance.yahoo.comAlector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD)September 9, 2022 | benzinga.comAmerican Axle & Mfg Hldgs (NYSE:AXL), Alector (NASDAQ:ALEC) – Enphase Energy, Immunocore And Some Other B - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address ALEC Company Calendar Last Earnings2/28/2023Today3/30/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees208Year Founded2013Price Target and Rating Average Stock Price Forecast$15.38 High Stock Price Forecast$41.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+144.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,310,000.00 Net Margins-99.77% Pretax Margin-97.33% Return on Equity-52.10% Return on Assets-15.37% Debt Debt-to-Equity RatioN/A Current Ratio7.74 Quick Ratio7.74 Sales & Book Value Annual Sales$133.62 million Price / Sales3.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.59 per share Price / Book2.42Miscellaneous Outstanding Shares83,030,000Free Float72,326,000Market Cap$521.43 million OptionableNot Optionable Beta0.83 Social Links Key ExecutivesArnon RosenthalChief Executive Officer & DirectorSaraswati Kenkare-MitraPresident, Head-Research & DevelopmentMarc Edward GrassoChief Financial, Accounting & Business OfficerCharles WolfusVP-Technology & Digital HealthGary RomanoChief Medical OfficerKey CompetitorsAgenusNASDAQ:AGENCoherus BioSciencesNASDAQ:CHRSEditas MedicineNASDAQ:EDITFate TherapeuticsNASDAQ:FATEiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsArnon RosenthalSold 15,186 sharesTotal: $94,456.92 ($6.22/share)Arnon RosenthalSold 5,849 sharesTotal: $48,663.68 ($8.32/share)Gary RomanoSold 3,238 sharesTotal: $26,940.16 ($8.32/share)Marc GrassoSold 1,291 sharesTotal: $10,741.12 ($8.32/share)Truist Financial CorpSold 1,985 shares on 2/17/2023Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions ALEC Stock - Frequently Asked Questions Should I buy or sell Alector stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares. View ALEC analyst ratings or view top-rated stocks. What is Alector's stock price forecast for 2023? 7 Wall Street analysts have issued 1 year price objectives for Alector's shares. Their ALEC share price forecasts range from $6.00 to $41.00. On average, they expect the company's share price to reach $15.38 in the next year. This suggests a possible upside of 152.0% from the stock's current price. View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts. How have ALEC shares performed in 2023? Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 33.9% and is now trading at $6.10. View the best growth stocks for 2023 here. When is Alector's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ALEC earnings forecast. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.09. The firm had revenue of $14.44 million for the quarter, compared to analyst estimates of $35.37 million. Alector had a negative net margin of 99.77% and a negative trailing twelve-month return on equity of 52.10%. What ETFs hold Alector's stock? ETFs with the largest weight of Alector (NASDAQ:ALEC) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Alector issued on next quarter's earnings? Alector updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $15.00 million-$25.00 million, compared to the consensus revenue estimate of $25.39 million. What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO). When did Alector IPO? (ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO. What is Alector's stock symbol? Alector trades on the NASDAQ under the ticker symbol "ALEC." Who are Alector's major shareholders? Alector's stock is owned by a number of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (2.93%), Price T Rowe Associates Inc. MD (2.09%), Franklin Resources Inc. (1.93%), Geode Capital Management LLC (1.44%), Braidwell LP (0.88%) and Morgan Stanley (0.72%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Orbimed Advisors Llc, Richard H Scheller, Robert King, Robert Paul, Shehnaaz Suliman and Terrance Mcguire. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alector's stock price today? One share of ALEC stock can currently be purchased for approximately $6.10. How much money does Alector make? Alector (NASDAQ:ALEC) has a market capitalization of $506.48 million and generates $133.62 million in revenue each year. The company earns $-133,310,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. How many employees does Alector have? The company employs 208 workers across the globe. Does Alector have any subsidiaries? The following companies are subsidiares of Alector: Alector LLC.Read More How can I contact Alector? Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com. This page (NASDAQ:ALEC) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.